Drug Trial Radar · NCT07910097
Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 15, 2026
Primary completion
Sep 1, 2028
Study completion Sep 1, 2029
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of Flurpiridaz F-18 positron emission tomography/computed tomography (PET/CT) as a diagnostic imaging tool to detect abnormal parathyroid glands in patients with primary hyperparathyroidism, prior to multi-parathyroid gland surgical exploration. Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi single photon emission computed computed tomography/computed tomography (SPECT/CT) imaging will be tested.
Conditions
- Hyperparathyroidism
Interventions
Flurpiridaz PET/CTDrug
Flurpiridaz is a FDA approved radiopharmaceutical used with PET/CT imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- SensitivityTime frame: 4 weeks
- sensitivityTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Unversity of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.